Johne's Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type (Cattle, Goat, Sheep), By Test Type (ELISA, PCR, AGID, Others), By End User (Veterinary Hospitals & Clinics, Others), By Region & Competition, 2021-2031F

January 2026 | 180 pages | ID: J590566BCB50EN
TechSci Research

Abstracts

The Global Johne?s Disease Diagnostics Market is projected to expand from USD 675.66 Million in 2025 to USD 987.55 Million by 2031, registering a CAGR of 6.53%. This sector encompasses testing platforms and analytical assays, such as polymerase chain reaction (PCR) and enzyme-linked immunosorbent assays (ELISA), specifically engineered to identify Mycobacterium avium subspecies paratuberculosis in livestock populations. The primary catalyst for this growth is the urgent need to address production losses, particularly those resulting from premature culling and diminished milk yields in infected herds. Additionally, strict trade protocols and herd health certification programs mandate frequent surveillance, forcing producers to maintain regular screening schedules. Highlighting the economic stakes, Animal Health Ireland reported in 2024 that the disease costs the Irish dairy industry between ?11.24 million and ?23.85 million annually, necessitating effective diagnostic solutions.

A major obstacle restricting broader market growth is the insufficient sensitivity of existing diagnostic methods during the disease's prolonged subclinical stage. Because infected animals often produce undetectable antibody levels or shed bacteria in low quantities for years, false-negative results are common, which hinders eradication efforts. This technical struggle to detect early-stage infection can erode producer trust in the efficacy of screening, subsequently postponing the widespread implementation of comprehensive testing regimes in cost-conscious livestock operations.

Market Driver

Technological innovations in rapid serological and molecular diagnostics are fundamentally transforming the market by satisfying the urgent requirement for sensitivity and speed in detecting Mycobacterium avium subspecies paratuberculosis. The rise of high-throughput PCR and phage-based technologies now permits the identification of viable bacteria significantly faster than legacy culture methods, which historically took months. For instance, the Animal Health Media Journal reported in November 2024, in an article titled 'New test detects Johne?s disease in day-old calves,' that a novel diagnostic system could identify active infection at least four weeks sooner than standard fecal PCR in 75% of trial instances. These advancements are crucial for interrupting transmission chains, allowing farmers to isolate infectious stock before they contaminate the environment and harm production metrics.

Furthermore, the enforcement of Government-Mandated Disease Control and Eradication Programs acts as a secondary major driver, making regular screening a standard operational necessity. These regulatory frameworks frequently tie market access to herd health status, obliging farmers to follow rigorous testing schedules to preserve trade certifications. As noted in 'Changes in the Johne?s Disease situation in GB dairy herds over 10 years' in Preventive Veterinary Medicine (August 2024), surveillance data indicated that the top 25% of herds with high average test values were responsible for 42% of all positive results, emphasizing the importance of centralized schemes in managing high-risk reservoirs. Moreover, these programs promote comprehensive management; according to the Journal of Dairy Science in 2024, incorporating young stock into testing protocols could decrease disease transmission by up to 30%, thereby boosting the global demand for diagnostic supplies.

Market Challenge

A significant impediment to the growth of the Global Johne?s Disease Diagnostics Market is the inadequate sensitivity of existing tools during the disease's extended subclinical phase. Since infected livestock frequently carry Mycobacterium avium subspecies paratuberculosis for years without generating adequate antibody responses or shedding detectable bacterial loads, standard assays often return false-negative results. This inability to accurately detect early-stage carriers damages producer confidence regarding the cost-efficiency of surveillance initiatives. When significant investments in screening fail to stop subsequent outbreaks because of undetected spreaders, livestock owners often hesitate to commit to the recurring testing schedules that generate market revenue.

This skepticism is further bolstered by data demonstrating low detection rates within managed populations. According to the Action Group on Johne?s, the mean prevalence of positive milk ELISA results in monitored herds across the United Kingdom was recorded at 2.7% in 2024. While this figure suggests effective management, it also underscores the challenge diagnostics face in revealing the broader reservoir of subclinical infection, thereby discouraging the widespread implementation of aggressive screening protocols among cost-sensitive farming operations.

Market Trends

The rise of AI-Powered MicroRNA Biomarker Technologies is revolutionizing the Global Johne?s Disease Diagnostics Market by resolving the sensitivity limitations inherent in traditional serology. In contrast to ELISA tests, which depend on lagging antibody production, microRNA profiling examines host-response gene expression to detect subclinical carriers before they become infectious. Utilizing machine learning algorithms, this molecular strategy enables the precise classification of early infection stages that standard assays miss. As reported by DVM360 in May 2025, in the article 'New diagnostic approach may help detect Johne disease in cattle earlier,' a newly validated AI-driven microRNA model achieved 71.8% accuracy in detecting Stage I and II infections, providing a vital tool for identifying silent spreaders and breaking transmission cycles.

Simultaneously, the integration of diagnostic testing with cloud-based herd management platforms is moving the industry from reactive diagnosis toward predictive risk stratification. Advanced software solutions now compile historical testing data to produce dynamic risk scores, enabling producers to foresee disease progression rather than simply responding to positive results. This digital shift supports algorithmic clustering to pinpoint high-risk animals that might be overlooked by standard protocols. According to Farmers Weekly in February 2025, in the article 'Johne?s risk detection improved with new data analysis tool,' predictive analytics showed that animals within specific high-risk data clusters were up to 1,000 times more likely to advance to an infectious state than low-risk counterparts, facilitating proactive biosecurity measures.

Key Market Players

• Zoetis Inc.
• Thermo Fisher Scientific, Inc.
• PBD Biotech Ltd
• IDEXX Laboratories, Inc.
• Innovative Diagnostics SAS
• VMRD Inc.
• BIOMeRIEUX S.A.
• INDICAL BIOSCIENCE GmbH
• Tetracore, Inc.
• Surefarm Ltd

Report Scope

In this report, the Global Johne's Disease Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Johne's Disease Diagnostics Market, By Animal Type
• Cattle
• Goat
• Sheep
• Johne's Disease Diagnostics Market, By Test Type
• ELISA
• PCR
• AGID
• Others
• Johne's Disease Diagnostics Market, By End User
• Veterinary Hospitals & Clinics
• Others
• Johne's Disease Diagnostics Market, By Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Johne's Disease Diagnostics Market.

Available Customizations:

Global Johne's Disease Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL JOHNE'S DISEASE DIAGNOSTICS MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Animal Type (Cattle, Goat, Sheep)
  5.2.2. By Test Type (ELISA, PCR, AGID, Others)
  5.2.3. By End User (Veterinary Hospitals & Clinics, Others)
  5.2.4. By Region
  5.2.5. By Company (2025)
5.3. Market Map

6. NORTH AMERICA JOHNE'S DISEASE DIAGNOSTICS MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Animal Type
  6.2.2. By Test Type
  6.2.3. By End User
  6.2.4. By Country
6.3. North America: Country Analysis
  6.3.1. United States Johne's Disease Diagnostics Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Animal Type
      6.3.1.2.2. By Test Type
      6.3.1.2.3. By End User
  6.3.2. Canada Johne's Disease Diagnostics Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Animal Type
      6.3.2.2.2. By Test Type
      6.3.2.2.3. By End User
  6.3.3. Mexico Johne's Disease Diagnostics Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Animal Type
      6.3.3.2.2. By Test Type
      6.3.3.2.3. By End User

7. EUROPE JOHNE'S DISEASE DIAGNOSTICS MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Animal Type
  7.2.2. By Test Type
  7.2.3. By End User
  7.2.4. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Johne's Disease Diagnostics Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Animal Type
      7.3.1.2.2. By Test Type
      7.3.1.2.3. By End User
  7.3.2. France Johne's Disease Diagnostics Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Animal Type
      7.3.2.2.2. By Test Type
      7.3.2.2.3. By End User
  7.3.3. United Kingdom Johne's Disease Diagnostics Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Animal Type
      7.3.3.2.2. By Test Type
      7.3.3.2.3. By End User
  7.3.4. Italy Johne's Disease Diagnostics Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Animal Type
      7.3.4.2.2. By Test Type
      7.3.4.2.3. By End User
  7.3.5. Spain Johne's Disease Diagnostics Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Animal Type
      7.3.5.2.2. By Test Type
      7.3.5.2.3. By End User

8. ASIA PACIFIC JOHNE'S DISEASE DIAGNOSTICS MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Animal Type
  8.2.2. By Test Type
  8.2.3. By End User
  8.2.4. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Johne's Disease Diagnostics Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Animal Type
      8.3.1.2.2. By Test Type
      8.3.1.2.3. By End User
  8.3.2. India Johne's Disease Diagnostics Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Animal Type
      8.3.2.2.2. By Test Type
      8.3.2.2.3. By End User
  8.3.3. Japan Johne's Disease Diagnostics Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Animal Type
      8.3.3.2.2. By Test Type
      8.3.3.2.3. By End User
  8.3.4. South Korea Johne's Disease Diagnostics Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Animal Type
      8.3.4.2.2. By Test Type
      8.3.4.2.3. By End User
  8.3.5. Australia Johne's Disease Diagnostics Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Animal Type
      8.3.5.2.2. By Test Type
      8.3.5.2.3. By End User

9. MIDDLE EAST & AFRICA JOHNE'S DISEASE DIAGNOSTICS MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Animal Type
  9.2.2. By Test Type
  9.2.3. By End User
  9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Johne's Disease Diagnostics Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Animal Type
      9.3.1.2.2. By Test Type
      9.3.1.2.3. By End User
  9.3.2. UAE Johne's Disease Diagnostics Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Animal Type
      9.3.2.2.2. By Test Type
      9.3.2.2.3. By End User
  9.3.3. South Africa Johne's Disease Diagnostics Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Animal Type
      9.3.3.2.2. By Test Type
      9.3.3.2.3. By End User

10. SOUTH AMERICA JOHNE'S DISEASE DIAGNOSTICS MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Animal Type
  10.2.2. By Test Type
  10.2.3. By End User
  10.2.4. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Johne's Disease Diagnostics Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Animal Type
      10.3.1.2.2. By Test Type
      10.3.1.2.3. By End User
  10.3.2. Colombia Johne's Disease Diagnostics Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Animal Type
      10.3.2.2.2. By Test Type
      10.3.2.2.3. By End User
  10.3.3. Argentina Johne's Disease Diagnostics Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Animal Type
      10.3.3.2.2. By Test Type
      10.3.3.2.3. By End User

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL JOHNE'S DISEASE DIAGNOSTICS MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Zoetis Inc.
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Thermo Fisher Scientific, Inc.
15.3. PBD Biotech Ltd
15.4. IDEXX Laboratories, Inc.
15.5. Innovative Diagnostics SAS
15.6. VMRD Inc.
15.7. BIOMeRIEUX S.A.
15.8. INDICAL BIOSCIENCE GmbH
15.9. Tetracore, Inc.
15.10. Surefarm Ltd

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER